OVID Ovid Therapeutics
- 1.050
- -0.010-0.94%
- 1.040
- -0.010-0.95%
Ovid Therapeutics News
Wedbush Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $4
Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Hold Rating
TD Cowen Maintains Ovid Therapeutics(OVID.US) With Buy Rating
Ovid Therapeutics: Strategic Developments and Financial Stability Lead to Buy Rating
Ovid Therapeutics | 10-Q: Q3 2024 Earnings Report
Ovid Therapeutics | 8-K: Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
Ovid Therapeutics Q3 2024 GAAP EPS $(0.20) Misses $(0.19) Estimate
Earnings Flash (OVID) OVID THERAPEUTICS Reports Q3 Revenue $173,000
Express News | Ovid Therapeutics Q3 Net Income USD -14.006 Million
Express News | Ovid Therapeutics Q3 Operating Expenses USD 13.399 Million
Press Release: Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results
Ovid Therapeutics to Host Investor Event
12 Health Care Stocks Moving In Wednesday's After-Market Session
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely?
H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $3
Buy Rating Affirmed for Ovid Therapeutics on Promising Safety Profile and Robust Pipeline Progress
B.Riley Financial Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Cuts Target Price to $3
Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Hold Rating
Oppenheimer Sticks to Their Hold Rating for Ovid Therapeutics (OVID)
BTIG Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $5
Analysis
Price Target
No Data
No Data